Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies

被引：0

作者：

Herbin, Shelbye R. ^{[1
]}

Crum, Hannah ^{[2
]}

Gens, Krista ^{[3
,4
]}

机构：

[1] John D Dingell VA Med Ctr, Antimicrobial Stewardship & Med Safety, 4646 John R St, Detroit, MI 48201 USA

[2] Mercy Hosp Southeast, Cape Girardeau, MO USA

[3] Allina Hlth, Minneapolis, MN USA

[4] Abbott NW Hosp, Minneapolis, MN USA

来源：

JOURNAL OF PHARMACY PRACTICE | 2024年 / 37卷 / 06期

关键词：

microbiome; Clostridioides difficile infection; Clostridioides difficile recurrence; fecal microbiota transplantation; antibiotics; PULSED FIDAXOMICIN; OPEN-LABEL; STRAIN M3; MICROBIOME; PREVENTION; TRANSPLANTATION; EPIDEMIOLOGY; VANCOMYCIN; GUIDELINES; SPORES;

D O I：

10.1177/08971900241248883

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Clostridioides difficile is a toxin-producing bacteria that is a main cause of antibiotic-associated diarrhea. Clostridioides difficile infections (CDI) are associated with disruptions within the gastrointestinal (GI) microbiota which can be further exacerbated by CDI-targeted antibiotic treatment thereby causing recurrent CDI (rCDI) and compounding the burden placed on patients and the healthcare system. Treatment of rCDI consists of antibiotics which can be paired with preventative therapeutics, such as bezlotoxumab or fecal microbiota transplants (FMTs), if sustained clinical response is not obtained. Newer preventative strategies have been recently approved to assist in restoring balance within the GI system with the goal of preventing recurrent infections.

引用

页码：1361 / 1373

页数：13

共 57 条

[1]

[Anonymous], 2023, EVALUATION CRS3123 V

[2]

[Anonymous], 2022, PERCENTAGE PEOPLE CO

[3]

[Anonymous], 2024, VE303 INTERNET

[4]

[Anonymous], 2022, OPEN LABEL EXTENSION

[5]

[Anonymous], 2023, VOWST FECAL MICROBIO

[6]

[Anonymous], 2022, REBYOTA (fecal microbiota, live-jslm) suspension, for rectal use prescribing information

[7]

[Anonymous], 2021, FINCH THERAPEUTICS A

[8]

Barbut F, 2000, J CLIN MICROBIOL, V38, P2386

[9] Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting [J].

Barbut, Frederic ;

Galperine, Tatiana ;

Vanhems, Philippe ;

Le Monnier, Alban ;

Durand-Gasselin, Bernard ;

Canis, Frederique ;

Jeanbat, Viviane ;

Duburcq, Anne ;

Alami, Sarah ;

Bensoussan, Caroline ;

Fagnani, Francis .

HEALTH AND QUALITY OF LIFE OUTCOMES, 2019, 17 (1)

[10] Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update [J].

Buetti, Niccolo ;

Marschall, Jonas ;

Drees, Marci ;

Fakih, Mohamad G. ;

Hadaway, Lynn ;

Maragakis, Lisa L. ;

Monsees, Elizabeth ;

Novosad, Shannon ;

O'Grady, Naomi P. ;

Rupp, Mark E. ;

Wolf, Joshua ;

Yokoe, Deborah ;

Mermel, Leonard A. .

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2022, 43 (05) :553-569

← 1 2 3 4 5 6 →